Vericel Expects Growth in Second Half 2020

Vericel's MACI orthobiologic

Vericel reported orthopedic revenue of USD $15.1 million, -27.5% vs. 2Q19. MACI implants declined -84% in April, -37% in May and then grew +21% in June compared to the prior year. Vericel believes that MACI is well-positioned to continue its growth in the second half of the year and beyond. Over 95% of MACI procedures are performed in...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us